• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylacetamides

Recent Advances in the Study of 1-(Phenylacetyl)piperidine-4-carboxylic Acid (CAS: 26965-32-2)

1-(Phenylacetyl)piperidine-4-carboxylic Acid (CAS: 26965-32-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This compound, characterized by its unique piperidine-carboxylic acid scaffold, has been investigated for its role in modulating biological pathways, particularly in the context of neurological and inflammatory disorders. Recent studies have focused on its synthesis, pharmacokinetics, and mechanism of action, providing valuable insights for drug development.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 1-(Phenylacetyl)piperidine-4-carboxylic Acid, highlighting its efficient production through a multi-step process involving acylation and carboxylation reactions. The study emphasized the compound's stability under physiological conditions, making it a promising candidate for further pharmacological evaluation. Additionally, the research team identified potential derivatives with enhanced bioavailability, opening new avenues for structural optimization.

In another groundbreaking study, researchers investigated the compound's interaction with gamma-aminobutyric acid (GABA) receptors, which are critical targets for treating anxiety and epilepsy. Using in vitro and in vivo models, the team demonstrated that 1-(Phenylacetyl)piperidine-4-carboxylic Acid exhibits moderate affinity for GABA_A receptors, suggesting its potential as a modulator of neuronal excitability. These findings were corroborated by molecular docking simulations, which revealed key binding interactions at the receptor's active site.

Beyond its neurological applications, recent research has also explored the anti-inflammatory properties of 1-(Phenylacetyl)piperidine-4-carboxylic Acid. A 2024 preprint article on bioRxiv reported that the compound significantly reduces the production of pro-inflammatory cytokines in macrophage cells, likely through the inhibition of NF-κB signaling. This dual functionality—targeting both neurological and inflammatory pathways—positions the compound as a versatile scaffold for multi-target drug design.

Despite these promising results, challenges remain in translating 1-(Phenylacetyl)piperidine-4-carboxylic Acid into clinical applications. Pharmacokinetic studies indicate limited blood-brain barrier penetration, which may restrict its efficacy in treating central nervous system disorders. However, ongoing research into prodrug formulations and nanoparticle-based delivery systems aims to address these limitations. Industry reports suggest that at least two pharmaceutical companies are currently evaluating the compound in preclinical trials for neurodegenerative diseases.

In conclusion, 1-(Phenylacetyl)piperidine-4-carboxylic Acid (CAS: 26965-32-2) represents a compelling case study in the intersection of chemical biology and drug discovery. Its diverse pharmacological profile and synthetic tractability make it a valuable tool for both academic research and industrial applications. Future studies should focus on optimizing its drug-like properties and elucidating its full therapeutic potential across multiple disease models.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)